Loading...
In 2004, a randomized trial suggested that valsartan (Diovan), an angiotensin-receptor blocker (ARB), was associated with excess risk for myocardial infarction (MI; JW Gen Med Jul 13 2004). In this systematic review and meta-analysis, investigators assessed whether risks for adverse cardiovascular (CV) and other outcomes were associated with use of ARBs.
The analysis included 37 randomized trials in which placebo or active antihypertensive treatments were compared with ARBs (147,000 patients with average follow-up of 3.3 years). Compared with placebo or active-treatment, ARBs were not associated with excess risk for all-cause death, CV-related death, or angina (relative risks, ≈1.0 for all outcomes). Furthermore, ARBs were not associated wit…